Navigation Links
CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
Date:9/16/2008

VIENNA, Va., Sept. 16 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (Amex: CVM) announced today that it expects to take delivery of the new manufacturing facility for its lead drug Multikine(R) on October 8, 2008. This dedicated facility will produce the Multikine that will be used for CEL-SCI's pivotal Phase III clinical trial for first-line therapy of previously untreated head and neck cancer patients, and subsequently for sale following approval of the drug. The facility, which cost about $22 million to build, is state of the art and commercial ready.

Geert Kersten, CEL-SCI's Chief Executive Officer said, "Multikine started with the idea that activating the immune system to fight cancer could be beneficial and successful, as long as you could activate the immune system before it was weakened by surgery, radiation and chemotherapy. Our clinical studies showed significant benefit to the cancer patients treated with Multikine. We are now in the home stretch. Having our own Multikine dedicated manufacturing facility gives us control and eliminates a great deal of risk from our product development."

CEL-SCI is developing Multikine for approval as a first line indication in head and neck cancer. To that end, the Company's upcoming Phase III clinical trial is an 800 patient clinical study designed to demonstrate that administration of its cancer drug Multikine to head and neck cancer patients before they receive any conventional cancer treatment will increase their survival. Head and neck cancer is one of the world's biggest cancers affecting about 650,000 people per annum worldwide.

About CEL-SCI's Phase III Cancer Drug Multikine:

In Phase II clinical trials Multikine was shown to be safe and well-tolerated, and to
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data Suggest CEL-SCIs CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis
2. CEL-SCI Corporation Reports First Quarter Financial Results
3. CEL-SCI Corporation Announces 2007 Financial Results
4. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
5. CEL-SCI to Present at Rodman & Renshaw 9th Annual Healthcare Conference
6. CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase
7. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
8. CEL-SCI CEO to Present Tomorrow at the Biotech / Pharma / Healthcare On-Line Forum
9. CEL-SCI Corporation Releases Letter to Shareholders
10. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
11. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014  Decision Resources Group finds that ... (ID) specialists are willing to prescribe Durata,s Dalvance ... use as OPAT, approximately two-thirds of the respondents ... their hospital inpatients. However, our findings indicate that ... initiated on OPAT following hospital discharge, and most ...
(Date:7/10/2014)... -- Decision Resources Group finds that over half of ... Drug Administration,s (FDA) approval of Vifor Fresenius Medical Care ... by the FDA in November 2013 for the treatment ... dialysis. Other key findings from the report ... : , Bundling: Based ...
(Date:1/15/2014)... Most osteoporosis patients want a choice in the ... sponsored by Mission Pharmacal Company. The survey, conducted by ... support community, revealed that 74 percent of osteoporosis patients ... form other than a pill or a tablet. ...
Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3
... YORK, July 13, 2011 Reportlinker.com announces ... available in its catalogue: ... 2011-2021 http://www.reportlinker.com/p0572968/Pharmaceutical-Wholesale-and-Distribution-Industry-World-Outlook-2011-2021.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Wholesali ... decade affect those activities? ...
... NATICK, Mass., July 12, 2011 RegenoCELL Therapeutics, Inc. ... F. Mongiardo, Chief Executive Officer, reported that plans are ... the United States and Europe for its stem cell ... Regenocell, Ltd., reported that it expects to begin marketing ...
Cached Medicine Technology:Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 2Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 3Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 4Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 5Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 6Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 7Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 8Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 9Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 10Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 11Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 12Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 13RegenoCELL Gives Second Half Update 2RegenoCELL Gives Second Half Update 3RegenoCELL Gives Second Half Update 4RegenoCELL Gives Second Half Update 5RegenoCELL Gives Second Half Update 6
(Date:7/12/2014)... (PRWEB) July 12, 2014 Fresh off their ... Colombia will meet on September 5th at Sun Life ... world to see some of the brightest stars in the ... fans in Miami will be treated to some of the ... is currently ranked as the third best team in the ...
(Date:7/12/2014)... July 12, 2014 In ... report, ‘cognitive assessment and training’ is defined ... assess, train, or enhance cognitive functions. These ... as in dementia screening, clinical trials, driver’s ... learning, self assessment, brain training, and employers’ ...
(Date:7/12/2014)... 12, 2014 Casinos in ... rising competition from international and online casinos. Revenue is ... the five years through 2014-15. Greater per capita gambling ... gaming services. Rises in discretionary income levels have also ... on non-essential items such as casino gambling services. Revenue ...
(Date:7/12/2014)... Pittsburgh, PA (PRWEB) July 12, 2014 “After my ... dad then had a stroke and loss the use of his ... wanted to design a way to help people like them enjoy ... he created a prototype for the PATRICIA CAROL HALL PLATE (P ... H PLATE) offers a more ergonomic way to eat for individuals ...
(Date:7/12/2014)... 12, 2014 Wright & Schulte LLC has ... , Inc., a subsidiary of Johnson & Johnson, on behalf ... pain after receiving a metal-on-metal DePuy Pinnacle hip replacement and ... the artificial hip implant. The DePuy hip lawsuit was filed ... of Texas (Case No. 3:14-cv-2427) where DePuy Pinnacle Hip ...
Breaking Medicine News(10 mins):Health News:Brazil Vs. Colombia Tickets Sun Life Stadium: Ticket Down Slashes Ticket Prices for Friendly Match Between Colombia and Brazil 2Health News:Brazil Vs. Colombia Tickets Sun Life Stadium: Ticket Down Slashes Ticket Prices for Friendly Match Between Colombia and Brazil 3Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 2Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 3Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 5Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 2Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 3Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 4Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 5
... medical center implemented strict protocols for administering gadolinium-based ... cases for nephrogenic system fibrosis (NSF). Implementing ... diminished kidney function says Dr. Ozden Narin, presenting ... had some patients who developed NSF after they ...
... 1. For Older COPD Patients, Long-acting Inhaled Beta-agonists ... such as inhaled beta-agonists and anticholinergic agents are ... (COPD). Both drugs have been shown to decrease ... function, quality of life, and possibly mortality. However, ...
... Exposure to secondhand smoke, such as a person can get ... has a direct, measurable impact on the brainand the effect ... person doing the smoking. In fact, exposure to this secondhand ... by the National Institute on Drug Abuse (NIDA), part of ...
... American workers forced to travel often on business aren,t doing their ... of U.S. researchers found that people who travel for business 20 ... disease than "light" travelers who were on the go only a ... School of Public Health analyzed the medical records of more than ...
... (BRONX, NY) In honor of his significant clinical ... the World Trade Center following the September 11, 2001 ... 2011 Public Service Award from the American Thoracic Society ... at Albert Einstein College of Medicine of Yeshiva ...
... CO Doctors have long sought a way to directly ... skull. Now researchers have developed a way to get the ... poker-chip that rests on a patient,s head, according to findings ... Academic Societies in Denver. "This is the first time ...
Cached Medicine News:Health News:Embargoed news from Annals of Internal Medicine 2Health News:Embargoed news from Annals of Internal Medicine 3Health News:Frequent Business Travel Tough on the Heart, Study Finds 2Health News:Einstein Montefiore lung specialist to receive award for work with 9/11 rescue workers 2Health News:Researchers develop device to measure brain temperature non-invasively 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: